Activation of the Extracytoplasmic Function $\sigma$ Factor $\sigma^V$ in Clostridioides difficile Requires Regulated Intramembrane Proteolysis of the Anti-$\sigma$ Factor RsiV

Anthony G. Pannullo,a Craig D. Ellermeiera,b

aDepartment of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
bGraduate Program in Genetics, University of Iowa, Iowa City, IA, USA

ABSTRACT Clostridioides (Clostridium) difficile is one of the leading causes of nosocomial diarrhea. Lysozyme is a common host defense against many pathogenic bacteria. C. difficile exhibits high levels of lysozyme resistance, which is due in part to the extracytoplasmic functioning (ECF) $\sigma$ factor, $\sigma^V$. It has been previously demonstrated that genes regulated by $\sigma^V$ are responsible for peptidoglycan modifications that provide C. difficile with high lysozyme resistance. $\sigma^V$ is not unique to C. difficile however, and its role in lysozyme resistance and its mechanism of activation has been well characterized in Bacillus subtilis where the anti-$\sigma$, RsiV, sequesters $\sigma^V$ until lysozyme directly binds to RsiV, activating $\sigma^V$. However, it remains unclear if the mechanism of $\sigma^V$ activation is similar in C. difficile. Here, we investigated how activation of $\sigma^V$ is controlled in C. difficile by lysozyme. We found that C. difficile RsiV was degraded in the presence of lysozyme. We also found that disruption of a predicted signal peptidase cleavage site blocked RsiV degradation and $\sigma^V$ activation, indicating that the site-1 protease is likely a signal peptidase. We also identified a conserved site-2 protease, RasP, that was required for site-2 cleavage of RsiV and $\sigma^V$ activation in response to lysozyme. Combined with previous work showing RsiV directly binds lysozyme, these data suggested that RsiV directly binds lysozyme in C. difficile, which leads to RsiV destruction via cleavage at site-1 by signal peptidase and then at site-2 by RasP, ultimately resulting in $\sigma^V$ activation and increased resistance to lysozyme.

IMPORTANCE Clostridioides difficile is a major cause of hospital-acquired diarrhea and represents an urgent concern due to the prevalence of antibiotic resistance and the rate of recurrent infections. We previously showed that $\sigma^V$ and the regulon under its control were involved in lysozyme resistance. We have also shown in B. subtilis that the anti-$\sigma$ RsiV acts as a direct sensor for lysozyme, which results in the destruction of RsiV and activation of $\sigma^V$. Here, we described the proteases required for degradation of RsiV in C. difficile in response to lysozyme. Our data indicated that the mechanism is highly conserved between B. subtilis and C. difficile.

KEYWORDS $\sigma$ factors, cell envelope, stress response, signal transduction, gene expression, sigma factors
colonizes the colon before a healthy microbiota can be reestablished (4, 5). The pathology of CDI is largely attributed to Toxin A and Toxin B, which glucosylate Rho GTPases. The toxins destroy the intestinal epithelium, inflammation, diarrhea, and, in some cases, lead to toxic megacolon (6, 7).

To survive, bacteria need to be able to adapt to a wide variety of environments each with unique stressors. Bacteria often express the genes required for stress responses only when required. Thus, many bacteria have developed specialized signaling systems to detect and respond to environmental stressors. These signaling systems can be quite varied and include large groups such as one-component systems, two-component systems, alternative sigma (σ) factors, and extracytoplasmic functioning (ECF) σ factors (8–12). ECF σ factors are a group of σ factors that are often involved in responding to external signals (8, 9, 13). ECF σ factor activity is often inhibited by a cognate anti-σ, which sequesters the ECF σ from RNA polymerase (RNAP) until the appropriate signal is detected. Once the signal is detected, the ECF σ is released from the anti-σ, via a variety of different mechanisms, including conformational change of the anti-σ which leads to release of the σ factor, a partner switching mechanism in which the anti-σ binds to a different substrate, which frees the ECF σ factor, and regulated intramembrane proteolysis (RIP) where the anti-σ is degraded by a series of proteases (14–17).

*C. difficile* encodes the ECF σ factor σV, which is responsible for detection and response to the innate host-factor lysozyme (18–20). σV controls expression of the peptidoglycan (PG) deacetylase PdaV, which, in conjunction with the peptidoglycan (PG) deacetylase PgaA, is responsible for conferring resistance to lysozyme in *C. difficile* (20, 21). This resistance is due to the deacetylation of the N-acetylglucosamine (NAG) residues of the PG. Under normal circumstances, lysozyme recognizes the repeating NAG and N-acetylmuramic acid (NAM) backbone of the PG and cleaves the β1-4 linkage between NAG and NAM resulting in cell lysis. However, when NAG residues become deacetylated lysozyme has a lower affinity for the PG backbone, which prevents lysozyme-mediated lysis (22). In *C. difficile*, when σV is fully activated approximately 90 to 95% of the NAG residues exist in a deacetylated state, providing resistance up to 16 mg/mL of lysozyme (18, 20, 21). In addition to pdaV, another gene found in the csfV operon, lbpA, has been shown to influence lysozyme resistance (20). LbpA is a RsiV ortholog and has been shown to bind lysozyme, but it lacks the σV binding domain and, thus, does not play a role in σV activation or regulation (20). However, it does act as a membrane-bound lysozyme binding protein that can confer resistance to low levels of lysozyme (20). It has also been shown that σV regulates the expression of lysozyme resistance genes outside the csfV operon, including the dltABCD operon. The dlt operon is partially regulated by σV, and, thus, responds to lysozyme. The dlt operon mediates lysozyme resistance through d-alanylation of lipid teichoic acids that protrude from the PG (23). This d-alanylation is predicted to drive the charge of the cell envelope to become less negative and reduce the affinity that lysozyme has for the PG (23). It has been shown that CRIPSRi knockdown of the dlt operon in *C. difficile* results in a ~16-fold decrease in lysozyme MIC (20).

σV is present in many Gram-positive bacteria, including the model organism *Bacillus subtilis*, where extensive work has been done to understand the mechanism of σV activation (24–29). In *B. subtilis* the anti-sigma factor of σV, RsiV, binds directly to lysozyme. The *C. difficile* and *Enterococcus faecalis* RsiV orthologs also directly bind lysozyme (29). Lysozyme binding is predicted to lead to conformational change within RsiV that initiates RIP of RsiV (25, 26). RIP generally consists of two-step proteolysis that utilizes a site-1 protease (S1P) and a site-2 protease (S2P) (13, 15, 30). In *B. subtilis* it was found that the S1P for RsiV are type 1 signal peptidases, specifically the major type 1 signal peptidases in *B. subtilis* SipS and SipT (27). Site-1 cleavage removes the extracellular portion of RsiV. However, the membrane-bound portion remains and continues to serve as a membrane anchor for σV, preventing activation. A second cleavage event is required to release RsiV from the membrane. This is carried out by the intramembrane
protease or S2P, which in *B. subtilis* is RasP (28). RasP is a conserved metalloprotease that exists in many bacteria and eukaryotes (30, 31). In addition to cleaving anti-σ factors, S2Ps also cleave remnant signal peptides to clear them from the membrane (32). After site-2 cleavage the remaining portion of RsiV complexed with σV is released into the cytosol, the vestiges of RsiV bound to σV are degraded likely via cytosolic proteases and σV is free to regulate its operon. This includes oatA, which is found in *B. subtilis* but not in *C. difficile* and encodes a peptidoglycan O-acetyltransferase, which increases lysozyme resistance by acetylating MurNac when expressed (24, 33, 34). While we know the mechanism of σV activation in *B. subtilis*, we do not know if this mechanism is conserved in *C. difficile*. In this study, we investigated the degradation of RsiV in response to lysozyme. We identified a *C. difficile* site-2 protease homolog, RasP, and showed that it was required for σV activation, lysozyme resistance, and RsiV degradation. We also demonstrated that *C. difficile* RsiV has a signal peptidase cleavage site and mutations in this site block RsiV degradation.

**RESULTS**

**C. difficile** RsiV is degraded in the presence of lysozyme. We previously demonstrated that *C. difficile* *csfV*, which encodes σV, is activated by lysozyme and is required for lysozyme resistance (18, 20). In *B. subtilis* and *E. faecalis* activation of σV requires the degradation of the anti-sigma factor, RsiV (28, 29, 35, 36). To demonstrate lysozymemediated activation of σV in *C. difficile*, we introduced a P_{pdaV}-RFP reporter plasmid in both wild-type (WT) and ΔcsfV strains. We incubated cells with increasing concentrations of lysozyme and measured the fluorescence. As previously reported, we found P_{pdaV} was induced by lysozyme in the WT and expression increased in response to increasing lysozyme concentrations (Fig. 1A) (20). In a ΔcsfV mutant, however, expression of the P_{pdaV} reporter was significantly lower than WT and was no longer induced in response to lysozyme (Fig. 1A) (20). To determine if σV activation correlated with lysozyme-induced degradation of RsiV in *C. difficile*, we constructed a P_{σV}-CFP-RsiV fusion protein. This allowed us to detect the fate of the N-terminal portion of RsiV and uncouple its production from σV activity because CFP-RsiV fusion would be induced by σV if expressed from its native promoter. We then monitored CFP-RsiV levels in cells incubated with increasing concentrations of lysozyme for 15 min. We found that CFP-RsiV levels decreased as lysozyme levels increased (Fig. 1B). Given the short time of incubation with lysozyme, it suggested that RsiV was degraded and this could be detected around 0.1 to 1 μg/mL of lysozyme (Fig. 1B). We note that decreasing RsiV levels and increasing σV activation appeared at similar lysozyme concentrations, suggesting that degradation of RsiV controls σV activation and expression of P_{pdaV}. This is well below the 8 to 16 mg/mL MIC of lysozyme, suggesting σV activation occurred at subinhibitory lysozyme concentrations (20).

Degradation of RsiV was dependent upon the presence of a signal peptidase cleavage site. RIP of an anti-σ factor is a common mechanism for activation of an ECF sigma (9, 13, 37). RIP consists of two major proteolytic events by site-1 and site-2 proteases (S1P, S2P), respectively. We previously identified the two major signal peptidases SipS and SipT as the proteases responsible for site-1 cleavage of RsiV in *B. subtilis* (27). In *B. subtilis*, site-1 cleavage of RsiV occurred at a signal peptide cleavage site located at the junction of the transmembrane and extracytoplasmic domains. The cleavage site is the typical ‘A-X-A’ motif present in most proteins cleaved by signal peptidases in *B. subtilis* (38). It should be noted that cleavage occurred directly after the recognized cleavage motif and not within the cleavage motif itself. We hypothesized that RsiV degradation in *C. difficile* functioned in a similar if not identical manner to *B. subtilis*.

We analyzed the sequence of RsiV using SignalP (39). We also performed a sequence alignment of RsiV from *B. subtilis* and *C. difficile* using Clustal Omega (40), focusing on the relative location of the *B. subtilis* signal peptide cleavage site. The alignment of the cleavage sites suggests that *C. difficile* RsiV could be cleaved between residues N71 and F72 (Fig. S1A). This would make the signal peptidase motif “A-X-N”. In contrast, SignalP
predicts the *C. difficile* RsiV cleavage site to be between residues A69 and D70 which would be a ‘V-X-A’ motif (Fig. 2B and Fig. S1B).

We sought to disrupt the putative signal peptide cleavage sites by introducing tryptophan residues at the putative -3, -1, and +1 positions to determine if changes to these residues blocked the degradation of RsiV. We constructed four variants of P_xyl-CFP-RsiV, which included WT, V67W, A69W, and N71W. Substitutions that convert the residues to bulky tryptophans will prevent recognition of the cleavage site, and it was shown to successfully block cleavage when performed in *B. subtilis* (29). We introduced these constructs into *C. difficile* and found that the WT and N71W mutant versions of CFP-RsiV were degraded in the presence of 20 µg/mL lysozyme (Fig. 2A). In contrast, the V67W and A69W mutants blocked the degradation of CFP-RsiV in the presence of lysozyme (Fig. 2A). This suggested that the ‘V-X-A’ motif and not the ‘A-X-N’ motif was likely the site-1 cleavage site. This also suggested that the cleavage site was likely between A69 and D70. This was consistent with the SignalP prediction and suggested that signal peptidases were the S1P for RsiV in *C. difficile* as they are in *B. subtilis*.

**The site-2 protease RasP was required for complete degradation of RsiV and maximal activation of α*.** As previously described, RIP mediated degradation of anti-α factors requires two proteolytic events, the second of which is performed by the conserved, membrane-embedded S2P (31). In *B. subtilis*, RasP is required for RIP mediated degradation of anti-α factors, including RsiW and RsiV (28, 41, 42). Because S2P are highly conserved, we used *B. subtilis* RasP to search for potential *C. difficile* S2P homologs using BLASTP (43). BLASTP revealed CDR20291_2036 (referred to as RasP) shared 38% amino acid identity to *B. subtilis* RasP (Fig. S2). Importantly, the metalloprotease active site motif, HEXXH, was highly conserved across different species as shown in Fig. S2, indicating that the two proteins likely function in a similar manner.
To determine if RasP was required for site-2 cleavage of RsiV in *C. difficile*, we constructed an in-frame deletion of *rasP* in the R20291 background using CRISPR editing (44). This deletion strain is referred to as ΔrasP. Using this deletion, we compared \( P_{pdaV} \)-RFP reporter activation, lysozyme MICs, and CFP-RsiV degradation in the WT and ΔcsfV strains to determine the role that RasP plays in *sV* signaling.

We found that the basal level activity of the \( P_{pdaV} \)-RFP reporter was reduced in the ΔrasP strain compared to the WT (Fig. 3A). However, \( P_{pdaV} \)-RFP activity was higher in ΔrasP compared to ΔcsfV (Fig. 3A). Expression of the \( P_{pdaV} \)-RFP activity was not significantly induced in response to low concentrations of lysozyme in the ΔrasP mutant (Fig. 3A). However, at higher concentrations of lysozyme, the increase in reporter activity in the ΔrasP mutant became significantly different compared to the no lysozyme control for the strains (Fig. 3A). However, this increase in reporter fluorescence was lower than the increase in fluorescence that was observed in the WT, indicating that RasP was required for maximal activation of the *csfV* operon (Fig. 3A).

We found the ΔrasP mutant also displayed a lower lysozyme MIC (4 to 8 mg/mL) compared to WT (approximately 16 to 32 mg/mL) (Fig. 3B). The decrease in lysozyme resistance of the ΔrasP mutant could be complemented by ectopic expression of rasP in the ΔrasP strain in which the lysozyme resistance was restored to the WT levels (Fig. 3B).

To determine if RasP was required for site-2 cleavage, we asked if the ΔrasP mutant led to the accumulation of the site-1 cleavage product. We expressed CFP-RsiV in the wild-type and ΔrasP mutant and then split the cultures to be treated with a range of lysozyme concentrations for 15 min. We found that treatment with lysozyme led to a buildup of partially cleaved CFP-RsiV in the ΔrasP mutant, which can be observed by the band that corresponds to \( \sim 30 \) kDa. This was consistent with the loss of site-2 protease activity (Fig. 3C). However, the loss of RasP did not appear to completely block site-2 cleavage of RsiV because the buildup of the intermediate product was not equivalent to the level of full-length RsiV in untreated cells. Taken together, these data suggested that RasP was required for optimal cleavage of RsiV at site-2 and, thus, \( \alpha^V \) activation in *C. difficile*. However, in the intermediate lysozyme resistance phenotype, the higher basal level of \( \alpha^V \) activity suggested another protease may be capable of cleaving RsiV at site-2.
In this work, we demonstrated that, in *C. difficile*, RsiV degradation and subsequent sV activation in the presence of lysozyme functions in a similar fashion as previously described in *B. subtilis* (27–29). We showed that in *C. difficile* RsiV was degraded in the presence of lysozyme in a dose-dependent manner. We also showed that, in *C. difficile*, RsiV was degraded through a RIP-mediated process similar to that in *B. subtilis* (27–29).

In *B. subtilis*, the S1P is signal peptidase, more specifically SipS and/or SipT, is a type-I signal peptidase (27). These peptidases were shown to cleave *B. subtilis* RsiV at a predicted signal peptide cleavage site, which follows a canonical ‘A-X-A’ motif commonly seen in *B. subtilis* secreted proteins (38). Here, we showed that *C. difficile* RsiV was likely cleaved at a signal peptide cleavage site, albeit of a slightly different motif than the one found in *B. subtilis*. Changing the residues in the signal peptide sequence to tryptophan residues completely prevented lysozyme-induced degradation of RsiV. The most likely explanation is that the signal peptidases are no longer able to recognize the cleavage site when tryptophan is present. It is interesting to note that the *C. difficile* signal peptide sequence is closer to the transmembrane domain than in *B. subtilis* however the functional consequence of that remains unclear.

*C. difficile* encodes three putative type-I signal peptidases. We have not established the signal peptidases in *C. difficile* that are responsible for site-1 cleavage of RsiV. Considering the conserved nature of the RsiV degradation and activation mechanisms between *C. difficile* and *B. subtilis* it seems reasonable to hypothesize that the signal peptidases in *C. difficile* could be redundant just as in *B. subtilis*. This is supported by...
Tn-seq data showing that none of the type-1 signal peptidases are essential as each of the putative signal peptidase encoding genes had multiple transposon insertions, suggesting there is functional redundancy as in \textit{B. subtilis} (45, 46).

We identified a RasP homolog based on conservation. However, it is worth noting that alignment of \textit{C. difficile} RasP to \textit{B. subtilis} RasP (Fig. S2) revealed that, while there is a great deal of homology, there are also some distinct differences. \textit{B. subtilis} RasP and \textit{E. faecalis} Eep contains an 89 amino acid insertion in a cytoplasmic domain (Fig. S2). This insertion is absent in both \textit{C. difficile} RasP and \textit{E. coli} RseP. RseP in \textit{E. coli} has two distinct PDZ domains on the extracellular face where RasP from \textit{C. difficile}, \textit{B. subtilis}, and \textit{E. faecalis} has a single PDZ domain. Since RasP is a highly conserved protease, even across different domains of life, it seemed very likely that RasP would be conserved in the degradation of Rsiv in \textit{C. difficile}. Indeed, our \textit{ΔrasP} mutant shows decreased \(\alpha^v\) activity in the presence of lysozyme compared to our WT. We were also able to detect the accumulation of the Rsiv degradation intermediate in the absence of RasP suggesting it is required for site-2 cleavage. Interestingly, the \textit{ΔrasP} mutant appears to exhibit intermediate phenotypes in both the \(P\) \textit{pdaV}-\textit{rfp} reporter and lysozyme MIC assays. In \textit{B. subtilis}, the activity of \(\alpha^v\) in a \textit{rasP} mutant is identical to the loss of \(\alpha^v\) itself (28). However, in \textit{C. difficile} this was not the case. We saw that, compared to a \textit{csIV} mutant, a \textit{ΔrasP} mutant had higher basal levels of \(\alpha^v\) activity. In addition, we saw the induction of \(\alpha^v\) activity in the presence of lysozyme in the \textit{ΔrasP} mutant, but the fold change was much lower than what occurs in the WT. We also observed that the Rsiv intermediate product band does not appear to become more intense with higher concentrations of lysozyme, which would be the anticipated phenotype. We hypothesize that other proteases can cleave Rsiv at site-2. However, these proteases are less efficient. This is supported by our data showing \textit{ΔrasP} mutants display intermediate phenotypes in the expression of \(P\) \textit{pdaV}-\textit{rfp} and sensitivity to lysozyme as well as a buildup of the site-1 cleavage product of Rsiv just not to levels of the full-length band. While there is a large number of similarities with \(\alpha^v\) activation in \textit{B. subtilis} the presence of additional proteases that can cleave Rsiv at site-2 is distinct. Additional work will be required to identify the other protease(s) in \textit{C. difficile} that can function as a site-2 protease for Rsiv in the absence of RasP.

\textbf{MATERIALS AND METHODS}

\textbf{Bacterial strains, media, and growth conditions.} Bacterial strains are listed in Table 1. The \textit{C. difficile} strains used in this study were derivatives of \textit{R20291}. \textit{C. difficile} strains were grown on tryptone-yeast (TY) medium supplemented as needed with thiamphenicol at 10 \(\mu\)g/mL (Thi10) and ampicillin at 50 \(\mu\)g/mL and cefoxitin at 50 \(\mu\)g/mL. TY consisted of 3% tryptone, 2% yeast extract and 2% agar (solid medium). \textit{C. difficile} strains were maintained at 37°C in an anaerobic chamber (Coy Laboratory Products) in an atmosphere of 10% \(H_2\), 5% \(CO_2\), and 85% \(N_2\).

\textit{E. coli} strains were grown in LB medium at 37°C with chloramphenicol at 10 \(\mu\)g/mL and ampicillin at 100 \(\mu\)g/mL as needed. LB contained 1% tryptone, 0.5% yeast extract, 0.5% NaCl, and 1.5% agar (solid medium).

\textbf{Plasmid and bacterial strain construction.} All plasmids are listed in Table 2 and Table S1. Plasmids were constructed using Gibson Assembly (New England Biolabs, Ipswich, MA). Regions of the plasmids constructed using PCR were verified by DNA sequencing. Oligonucleotide primers used in this work were synthesized by Integrated DNA Technologies (Coralville, IA) and are listed in Table S2. All plasmids were propagated using OmniMax-2 T1R as a cloning host. CRISPR-Cas9 deletion plasmids were passaged in \textit{E. coli} strain MG1655 before transformation into \textit{B. subtilis}. CRISPR-Cas9 plasmids were built on the backbone of pJK02 (44) with some modifications (20).

For xylose-inducible overexpression constructs, genes of interest were amplified using PCR, the oligonucleotides are listed in Table S2. PCR amplicons were then inserted into the plasmid pAP114 at the Saci and BamHI sites, as described previously (47).

\textbf{Lysozyme MIC determination.} Overnight cultures of \textit{C. difficile} were subcultured, grown to late log phase (optical density at 600 nm [OD\textsubscript{600}] of 1.0), and then diluted into TY to 10\textsuperscript{8} CFU/mL. For samples that were preincubated with lysozyme, lysozyme was added at the time and concentration indicated. A series of lysozyme concentrations were prepared in a 96-well plate in 50 \(\mu\)L TY broth. Wells were inoculated with 50 \(\mu\)L of the dilute late-log-phase culture (0.5 \(\times\) 10\textsuperscript{8} CFU/well) and grown at 37°C for 16 h. Each well was then sampled by removing 10 \(\mu\)L and diluting 1:10 in TY broth, and 5 \(\mu\)L of this dilution was spotted onto TY agar and incubated at 37°C for 24 h. The MIC was defined as the lowest concentration of lysozyme at which 5 or fewer colonies were found per spot.
TABLE 1 Strains

| Species and strain | Genotype and/or description | Source or reference* |
|--------------------|-----------------------------|----------------------|
| E. coli            | F− (proA8: lacIq lacZ ΔM15 Tn10(TetR) Δ(cdaAB) mcrA Δ(mrr-hsdR517-mcrBC) φ80 Δ(lacZY-ArgF) U169 endA1 recA1 supE44 thi-1 gyrA96 relA1 tonA panD) | Invitrogen           |
|                   | HB101/pRK24 F− mcrB mrr hsdS20 (R− mB−) recA13 leuB6 ara-14 proA2 lacY1 galK2 xyl-5 mtl-1 rpsL20 | (51)                 |
|                   | MG1655 Wild type            | (52)                 |

**B. subtilis**

| Strains     | Source or reference* |
|-------------|----------------------|
| BS49        | Tn916 donor strain, TetR | (53) |

**C. difficile**

| Strains     | Source or reference* |
|-------------|----------------------|
| R20291      | Wild-type strain from UK outbreak (ribotype 027) | (54) |
| CDE2966     | R20291 ΔcasF | (20) |
| AP150       | R20291 ΔrasP | (20) |
| GMK208      | R20291/pRAN738 (P_{pdaV}/rfp) | (20) |
| GMK211      | R20291 ΔcasF/P_{pRAN738} (P_{pdaV}/rfp) | (20) |
| AP153       | R20291 ΔrasP/P_{pRAN738} (P_{pdaV}/rfp) | (20) |
| AP151       | R20291 ΔrasP/P_{CEF620} (P_{pRF-CFP-RsiV}) | (20) |
| AP441       | R20291/P_{AP114} (P_{pRF-cfp}) | (20) |
| AP230       | R20291 ΔrasP/P_{CEF675} (P_{pRF-rasP}) | (20) |
| AP131       | R20291/P_{CEF627} (P_{pRF-CFP-RsaP^{mCherry}}) | (20) |
| AP126       | R20291/P_{CEF621} (P_{pRF-CFP-RsiV^{mCherry}}) | (20) |
| AP127       | R20291/P_{CEF622} (P_{pRF-CFP-RsiV^{mCherry}}) | (20) |

*Unless noted strains were generated as part of this study.

**Fixation protocol.** Cells were fixed as previously described (48–50). Briefly, a 500 μL aliquot of cells grown in TY broth was added to a 100 μL solution of 16% paraformaldehyde (Alfa Aesar) and 20 μL of 1 M NaPO₄ buffer (pH 7.4). The sample was mixed, removed from the chamber, and incubated in the dark at room temperature for 60 min. The samples were washed 3 times with phosphate-buffered saline (PBS) resuspended in 100 μL PBS, and left in the dark for a minimum of 3 h to allow for maturation of the chromophore.

**Fluorescence measurements with a plate reader.** Fluorescence from bulk samples was measured using an Infinite M200 Pro plate reader (Tecan) as previously described (49, 50). Briefly, fixed cells in PBS were added to a 96-well microtiter plate (black, flat optical bottom). Fluorescence was recorded as follows: excitation at 554 nm, emission at 610 nm, and gain setting at 140. The cell density (OD₆₀₀) was also recorded and used to normalize the fluorescence reading.

**Immunoblot analysis.** Cultures were grown to mid-log phase (OD₆₀₀ ~ 0.7) in TY +1% xylose at which point 20 μg/mL of lysozyme was added to cultures and incubated for 15 min before sample preparation. Samples were suspended in 200 μL of 2× Laemmli sample buffer and sonicated with a Branson Sonifier 450. Samples were electrophoresed on a 15% SDS-polyacrylamide gel which was run at 150V for approximately 90 min. Proteins were then blotted onto a nitrocellulose membrane at 100 mA for 1 h. (Bio-Rad). Nitrocellulose was blocked with 5% bovine serum albumin (BSA) in transfer buffer, and proteins were detected with 1:10,000 anti-GFP antiserum. Streptavidin IR800LT (1:10,000) was used to detect the biotinylated protein AccC which served as a loading control and has a size of ~150 kDa. To detect primary antibodies, the blots were incubated with 1:10,000 goat anti-rabbit IR800CW (Li-Cor) and imaged on an Azure Sapphire imager (Azure Biosystems). All immunoblot assays were performed a minimum of three times with a representative example being shown.

TABLE 2 Plasmids

| Plasmid | Relevant features | Reference |
|---------|-------------------|-----------|
| pRPF185 | E. coli-C. difficile shuttle vector with the tetracycline-inducible promoter; P_{pRPF-862} cat D6ori RP4oriT-traJ pMB1 ori | (54) |
| pRAN738 | P_{pRF-862}mCherryOpt cat | (20) |
| AP114   | P_{pRF-862}mCherryOpt cat | (47) |
| AP357   | P_{pRF-cfp} cat | (48) |
| pCE641  | P_{pRF-862}cas9-opt ΔrasP P_{pRF-862}sgRNA-rasP catP | (20) |
| pAP109  | P_{pRF-862}cas9-opt ΔrasP P_{pRF-862}sgRNA-rasP catP | (20) |
| pCE675  | P_{pRF-862}rasP cat | (20) |
| pCE620  | P_{pRF-862}rfp cat | (20) |
| pCE621  | P_{pRF-862}rfp^{mCherry} cat | (20) |
| pCE622  | P_{pRF-862}rfp^{mCherry} cat | (20) |
| pCE627  | P_{pRF-862}rfp^{mCherry} cat | (20) |
REFERENCES
1. Centers for Disease Control and Prevention (U.S.). 2019. Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention (U.S.). https://www.cdc.gov/drugresistance/rtr/rtr2019-2.pdf. Revised 4 January 2022.
2. Kelly CP, Poohoulakis C, LaMont JT. 2010. Clostridium difficile colitis. Review article. Massachusetts Medical Society. https://www.nejm.org/doi/10.1056/NEJMc1001273. Retrieved 31 August 2021.
3. Slimsing C, Riley TV. 2014. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 69:881–891. doi:10.1093/jac/dkt477.
4. Bauer MP, Notermans DW, van Bentheim BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dessel JT, Kuijper EJ. 2011. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377:63–73. https://doi.org/10.1016/S0140-6736(10)61266-4.
5. Comely OA, Miller MA, Louie TJ, Grobsh DL. 2012. Treatment of first recurrence of Clostridium difficile infection: fidaxomycin versus vancomycin. Clin Infect Dis 55:S154–S161. doi:10.1093/cid/crs462.
6. Just I, Gerhard R. 2005. Large clostridial cytotoxins, p 23 in Bacillus subtilis. Springer, Berlin, Heidelberg.
7. Gerhard R, Nottrott S, Schaotenbaue J, Tatge H, Olling A, Just I. 2008. 2008. Glucosylation of Rho GTPases by extracytoplasmic function (ECF) toxins. A triggers apoptosis in intestinal epithelial cells. J Med Microbiol 57:765–770. https://doi.org/10.1099/jmm.0.47769-0.
8. Staro A, Sofía HJ, Dietrich S, Ulrich LE, Liesegang H, Mascher T. 2009. The third pillar of bacterial signal transduction: classification of the extracytoplasmic function (ECF) sigma factor protein family. Mol Microbiol 74:557–581. doi:10.1111/j.1365-2958.2009.06870.x.
9. Helmann JD. 2002. The extracytoplasmic function (ECF) sigma factors. Adv Microb Physiol 46:47–110. https://doi.org/10.1016/S0065-2911(02)46002-X.
10. Ulrich LE, Koonin EV, Zhulin IB. 2005. One-component systems dominate signal transduction in prokaryotes. Trends Microbiol 13:52–56. https://doi.org/10.1016/j.tim.2004.12.006.
11. Stock AM, Robinson VL, Goudreau PN. 2000. Two-component signal transduction. Annu Rev Biochem 69:183–215. https://doi.org/10.1146/annurev.biochem.69.1.183.
12. Mascher T, Helmann JD, Unden G. 2006. Stimulus perception in bacterial signal-transducing histidine kinases. Microbiol Mol Biol Rev 70:910–938. https://doi.org/10.1128/MMBR.00020-06.
13. Ho TD, Ellermeier CD. 2012. Extra cytoplasmic function factor activation. Curr Opin Microbiol 15:182–188. https://doi.org/10.1016/j.mib.2012.01.001.
14. Mascher T. 2013. Signalling diversity and evolution of extracytoplasmic function (ECF) sigma factors. Curr Opin Microbiol 16:148–155. https://doi.org/10.1016/j.mib.2013.02.001.
15. Helmann JD. 2016. Bacillus subtilis extracytoplasmic function (ECF) sigma factors and defense of the cell envelope. Curr Opin Microbiol 30:122–132. https://doi.org/10.1016/j.mib.2016.02.002.
16. Sineva E, Savkina M, Ades SE. 2017. Themes and variations in genes regulation by extracytoplasmic function (ECF) sigma factors. Curr Opin Microbiol 36:128–137. https://doi.org/10.1016/j.mib.2017.05.004.
17. Haste JL, Ellermeier CD. 2016. Proteolytic activation of extra cytoplasmic function (ECF) sigma factors. Pp 344–351. In Stress and Environmental Regulation of Gene Expression and Adaptation in Bacteria. John Wiley & Sons, Inc., Hoboken, NJ, USA.
18. Ho TD, Williams KB, Chen Y, Helm RF, Popham DL, Ellermeier CD. 2014. Clostridium difficile extracytoplasmic function factor alpha factor is regulated by lysozyme resistance and is necessary for pathogenesis in the hamster model of infection. Infect Immun 82:2345–2355. https://doi.org/10.1128/IAI.01483-13.
19. Ho TD, Ellermeier CD. 2011. PrsW is required for colonization, resistance to antimicrobial peptides, and expression of extracytoplasmic function sigma factors in Clostridium difficile. Infect Immn 79:3229–3238. https://doi.org/10.1128/IAI.00019-11.
20. Kaus GM, Snyder LF, Müh U, Flores MJ, Popham DL, Ellermeier CD. 2020. Lysozyme resistance in Clostridium difficile is dependent on two peptidoglycan deacetylases. J Bacteriol 202:e00421-20. https://doi.org/10.1128/JB.00421-20.
21. Coullon H, Rifflet A, Wheeler R, Janoir C, Boneca IG, Candela T. 2020. Peptidoglycan analysis reveals that synergistic deacetylase activity in vegetative Clostridium difficile impacts the host response. J Biol Chem 295:16785–16796. https://doi.org/10.1074/jbc.RA119.012442.
22. Blake CCF, Koenig DF, Mair GA, North ACT, Phillips DC, Samra VR. 1965. Structure of hen egg-white lysozyme: a three-dimensional fourier synthesis at 2 Å resolution. Nature 206:757–761. https://doi.org/10.1038/206757a0.
23. Woods EC, NAWROCKI KL, SUÁREZ JM, McBride SM. 2016. The Clostridium difficile Dlt pathway is controlled by the extracytoplasmic function sigma factor alpha factor in response to lysozyme. Infect Immn 84:1902–1916. https://doi.org/10.1128/IAI.00207-16.
24. Ho TD, Haste JL, Intile PJ, Ellermeier CD. 2011. The Bacillus subtilis extracytoplasmic function sigma factor is induced by lysozyme and provides resistance to lysozyme. J Bacteriol 193:6215–6222. https://doi.org/10.1128/JB.00546-11.
25. Haste JL, Williams KB, Bohr LL, Houtman JC, Gahak L, Ellermeier CD. 2016. The anti-sigma factor RsiV is a bacterial receptor for lysozyme: co-crystal structure determination and demonstration that binding of lysozyme to RsiV is required for alpha factor activation. PLoS Genet 12:e1006287. https://doi.org/10.1371/journal.pgen.1006287.
26. LERWeker LT, KIES PJ, Müh U, Ellermeier CD. 2018. Bacterial sensing: a putative amphipathic helix in RsiV is the switch for activating alpha factor in response to lysozyme. PLoS Genet 14:e1007527. https://doi.org/10.1371/journal.pgen.1007527.
27. CASTRO AN, LERWeker LT, HASTE JL, ELLermeier CD. 2018. Signal peptidase is necessary and sufficient for site 1 cleavage of RsiV in Bacillus subtilis in response to lysozyme. J Bacteriol 200:e00663-17. https://doi.org/10.1128/JB.00663-17.
28. Haste JL, Williams KB, Ellermeier CD. 2014. Alpha activity of extracytoplasmic function sigma factor Bacillus subtilis, Is controlled by regulated proteolysis of the anti-alpha factor RsiV. J Bacteriol 195:3135–3144. https://doi.org/10.1128/JB.02224-13.
29. Haste JL, Williams KB, Sepulveda C, Houtman JC, Forest KT, Ellermeier CD. 2014. Evidence of a bacterial receptor for lysozyme: binding of lysozyme to the anti-alpha factor RsiV controls activation of the ECF sigma factor. J Bacteriol 196:696–703. https://doi.org/10.1128/jb.03611-13.
30. Brown MS, Ye J, Rawson RB, Goldstein JL. 2000. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100:391–398. https://doi.org/10.1016/s0092-8674(00)80675-3.

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.

FIG S1, TIF file, 2 MB.
FIG S2, TIF file, 1.8 MB.
TABLE S1, PDF file, 0.1 MB.
TABLE S2, PDF file, 0.1 MB.

ACKNOWLEDGMENTS
This work was supported by the National Institutes of Allergy and Infectious Disease NIH R01AI087384 (CDE), and AP was supported by T32AI007511. We thank members of the Ellermeier lab for their helpful comments. We declare no conflict of interest.
Activation of \( \alpha^V \) in Clostridioiides difficile

32. Saito A, Hizukuri Y, Matsuo E, Chiba S, Mori H, Nishimura O, Ito K, Akiyama Y, 2011. Post-ribosomal cleavage of signal peptides is catalyzed by the site-2 protease (SP2) in bacteria. Proc Natl Acad Sci U S A 108: 13740–13745. https://doi.org/10.1073/pnas.1108376108.

33. Laaberki M-H, Pfeffer J, Clarke AJ, Dworkin J. 2011. O-acetylation of peptidoglycan is required for proper cell separation and S-layer anchoring in Bacillus anthracis. J Biol Chem 286:5278–5288. https://doi.org/10.1074/jbc.M110.183236.

34. Guariglia-Dropeza V, Helmann JD. 2011. Bacillus subtilis \( \alpha^V \) confers lysozyme resistance by activation of two cell wall modification pathways, peptidoglycan O-acetylation and d-alanylation of teichoic acids. J Bacteriol 193:6223–6232. https://doi.org/10.1128/JB.06023-11.

35. Paget MS. 2015. Bacterial sigma factors and anti-sigma factors: structure, function and distribution. Biomolecules 5:245–3134. https://doi.org/10.1128/JB.00291-13.

36. Parthasarathy S, Wang X, Carr KR, Varahan S, Hancock EB, Hancock LE. SigV mediates lysozyme resistance in Enterococcus faecalis via the activation of the extracytoplasmic function sigma factor SigV. J Bacteriol 195:3125–3134. https://doi.org/10.1128/JB.00291-13.

37. Tjalsma H, Bolhuis A, Jongbloed JDH, Bron S, van Dijl JM. 2000. Signal peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the secretome. Microbiol Mol Biol Rev 64:515–547. https://doi.org/10.1128/MMBR.64.3.515-547.2000.

38. Almagro Armenteros JJ, Tsirigos KD, Sønderby CK, Petersen TN, Winther O, Brunak S, von Heijne G, Nielsen H. SignalP 5.0 improves signal peptide predictions using deep neural networks. Nat Biotechnol 37: 420–423. https://doi.org/10.1038/s41587-019-0036-z.

39. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J, Thompson JD. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539. https://doi.org/10.1038/msb.2011.75.

40. Heinrich J, Hein K, Wiegert T. 2009. Two proteolytic modules are involved in regulated intramembrane proteolysis of Bacillus subtilis RsiW: site-1 proteolysis of RsiW by RsiW, Mol Microbiol 74:1412–1426. https://doi.org/10.1111/j.1365-2958.2009.06940.x.

41. Schöbel S, Zellmeier S, Schumann W, Wiegert T. 2004. The Bacillus subtilis \( \alpha^V \) anti-sigma factor RsiW is degraded by intramembrane proteolysis through YuC. Mol Microbiol 52:1091–1105. https://doi.org/10.1111/j.1365-2958.2004.04031.x.

42. McAllister KN, Boullaut L, Kahn JN, Self WT, Sorg JA. 2017. Using CRISPR-Cas9-mediated genome editing to generate C. difficile mutants defective in selenoproteins synthesis. Sci Rep 7:14672. https://doi.org/10.1038/s41598-017-15236-5.

43. Dembek M, Barquist L, Boinett CJ, Cain AK, Mayho M, Lawley TD, Fairweather NF, Fagan RP. 2015. High-throughput analysis of gene essentiality and sporulation in Clostridium difficile. mBio 6:e02383-14. https://doi.org/10.1128/mBio.02383-14.

44. McAllister KN, Boullaut L, Kahn JN, Self WT, Sorg JA. 2017. Using CRISPR-Cas9-mediated genome editing to generate C. difficile mutants defective in selenoproteins synthesis. Sci Rep 7:14672. https://doi.org/10.1038/s41598-017-15236-5.